InfraReDx’s LipiScan™ IVUS Coronary Imaging System to be Highlighted at the American College of Cardiology 60th Annual Scientific Session and Innovation in Intervention

— Company’s Intelligent Imaging Technology to be Showcased in Series of Presentations at ACC.11 and i2 Summit —

BURLINGTON, Mass. (March 28, 2011) – InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several oral and poster presentations during the American College of Cardiology 60th Annual Scientific Session (ACC.11) and Innovation in Intervention 2011 (i2 Summit), being held April 2-5, 2011 at the Ernest N. Morial Convention Center in New Orleans. The LipiScan IVUS Coronary Imaging System is the world’s first and only intravascular imaging system that combines and co-registers grayscale intravascular ultrasound (IVUS) with the company’s proprietary near infrared spectroscopy lipid core plaque detection technology.

“We are pleased with the level of interest the LipiScan IVUS has received since its launch last year, and we look forward to the numerous presentations highlighting this novel product at ACC.11 and the i2 Summit,” said Donald Southard, InfraReDx president and chief executive officer. “The LipiScan IVUS permits physicians to identify both the structure – with IVUS – and chemistry – with LipiScan – of coronary plaques in a single pullback. The IVUS information is useful for determining the degree of stenosis and for guiding stenting, while the LipiScan data can identify stenotic lipid core plaques, which are at increased risk of causing peri-stenting myocardial infarction when dilated.”

In addition to the oral and poster presentations, James E. Muller, M.D., InfraReDx founder, chairman and chief medical officer, will give a presentation titled “Multimodality Near-infrared Spectroscopy and IVUS Coronary Imaging: Strategies to Prevent the First Coronary Event and Improve Coronary Stenting” during the Cardiovascular Innovations Forum at 9:30 a.m. on April 3. The Forum will be held in the ACC Exhibition area in Hall C, booth 2801, and a question and answer session will immediately follow Dr. Muller’s presentation.

The company will also be exhibiting at booth #4427 during the conference.

The schedule of oral and poster presentations at ACC.11 and i2 Summit is as follows:

**Oral Presentations:**

<table>
<thead>
<tr>
<th>Presentation Date/Time:</th>
<th>Sunday, April 3, 5:05-5:15 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session Title:</td>
<td>Identification of High Risk Plaques and Predictors of Distal Embolization: IVUS, OCT, Spectroscopy and Beyond</td>
</tr>
<tr>
<td>Presenter:</td>
<td>James A. Goldstein, M.D, director of research and education, Division of Cardiology, William Beaumont Hospital</td>
</tr>
<tr>
<td>Topic:</td>
<td>Intravascular Imaging: Uses During Percutaneous Coronary Intervention</td>
</tr>
<tr>
<td>Session Type/Location:</td>
<td>i2 Symposium, Session #2609-5, Room 350</td>
</tr>
</tbody>
</table>
### Presentation Date/Time:
Monday, April 4, 11:41-11:55 a.m.

**Session Title:**
Association Between the Presence and Extent of Coronary Lipid Core Plaques Detected by Near-Infrared Spectroscopy with Post Percutaneous Coronary Intervention Myocardial Infarction

**Presenter:**
Deepa Raghunathan, medical student, Texas A&M Health Science Center College of Medicine

**Topic:**
PCI in ACS and AMI

**Session Type/Location:**
i2 Oral Contributions, Session #2906-9, Room 353

---

### Panel Date/Time:
Monday, April 4, 12:30-1:45 p.m.

**Panelist:**
Brijeshwar Singh Maini, M.D., F.A.C.C., chair, Structural Heart Program, and co-chair, cardiovascular research, Pinnacle Health System

**Topic:**
Intravascular Imaging Case Reviews

**Session Type/Location:**
i2 Meet the Experts, Session #2308-4, Room 350

---

### Presentation Date/Time:
Monday, April 4, 5:15-5:27 p.m.

**Session Title:**
Coronary Artery Computed Tomography Angiography: Comparison to Intravascular Ultrasound

**Presenter:**
James A. Goldstein, M.D., director of research and education, Division of Cardiology, William Beaumont Hospital

**Topic:**
Atherosclerosis and Imaging

**Session Type/Location:**
ACC Symposium, Session #0653-7, Room 221

---

### Poster Presentation:
Sunday, April 3, 3:30-4:45 p.m.

**Session Title:**
Intracoronary Lipid Burden at Bifurcations: Results from the COLOR Registry

**Presenter:**
Jacob Townsend, M.D., cardiology fellow, Medical University of South Carolina

**Topic:**
Cardiovascular Risk Factors

**Session Type/Location:**
ACC Poster Contributions, Session #1041-119, Hall F

Sessions are embargoed until time of presentation.

### About the LipiScan™ IVUS Coronary Imaging System
The LipiScan IVUS Coronary Imaging System employs proprietary optical imaging technology to overcome the challenges of heart motion, blood interference, and vascular access to perform NIR spectroscopic analysis of the vessel and produce a chemical map of lipid-core plaque called a Chemogram™. The system also provides physicians with a traditional IVUS image that shows plaque location, degree of stenosis and degree of stent expansion. At the same time, optical data are recorded that permit identification and co-localization of lipid core plaques. This innovative multi-modality analysis is accomplished directly in the catheterization laboratory during the coronary intervention via a single catheter pullback procedure. The data are immediately available to the physician to help guide the stenting procedure.

### About InfraReDx, Inc.
InfraReDx, Inc. is a privately funded medical device company improving patient care through the development and commercialization of intelligent imaging technologies to improve the diagnosis and treatment of coronary artery disease. InfraReDx’s LipiScan™ IVUS Coronary Imaging System includes the first and only available catheter to combine both near-infrared spectroscopy (NIR) and intravascular ultrasound (IVUS) technologies to both visualize and characterize the intracoronary lipid core plaques (LCP) demonstrated to complicate stenting and suspected of causing the majority of heart attacks. Founded in 1998, InfraReDx is headquartered in Burlington, Massachusetts. For more information, visit www.infraredx.com.

Contacts:
Susan Heins (media) Grant Frazier
Pure Communications, Inc. Vice President of Marketing
864-286-9597 InfraReDx, Inc.
sjheins@purecommunicationsinc.com 781-345-9632
gfrazier@infraredx.com

Source: InfraReDx, Inc.

# # #